Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced receiving clinical trial approval in China for its 9MW3911, a non-IL-2 blocking CD25 monoclonal antibody (mAb). The National Medical Products Administration (NMPA) has given the go-ahead for the drug to be assessed as a treatment for advanced malignant tumors.
9MW3911: A Selective Approach to Tumor Immunity
Developed on Mabwell’s high-efficiency B lymphocyte screening platform, 9MW3911 is designed to selectively clear regulatory T cells (Treg) that highly express CD25 through antibody-dependent cell-mediated cytotoxicity (ADCC). This innovative approach does not block the IL-2 signaling pathway, allowing for the regulation of the tumor microenvironment and the enhancement of tumor immunity without interfering with essential immune cell functions.
Preclinical Studies Indicate Promising Efficacy and Safety
Preclinical studies on 9MW3911 have yielded positive indications of efficacy and safety, making it a promising candidate for further development and clinical trials. The ability of 9MW3911 to modulate the immune response in the tumor microenvironment without disrupting the IL-2 pathway could offer a new therapeutic option for patients with advanced malignant tumors.-Fineline Info & Tech
